Bank of New York Mellon Corp Has $5.75 Million Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Bank of New York Mellon Corp lessened its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 8.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 850,636 shares of the company’s stock after selling 75,482 shares during the period. Bank of New York Mellon Corp owned about 0.22% of Recursion Pharmaceuticals worth $5,750,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. IFP Advisors Inc increased its stake in Recursion Pharmaceuticals by 170.4% in the 4th quarter. IFP Advisors Inc now owns 11,831 shares of the company’s stock valued at $80,000 after buying an additional 7,455 shares during the last quarter. Colonial River Investments LLC purchased a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at $68,000. Handelsbanken Fonder AB grew its position in shares of Recursion Pharmaceuticals by 5.9% during the 4th quarter. Handelsbanken Fonder AB now owns 73,600 shares of the company’s stock valued at $498,000 after purchasing an additional 4,100 shares in the last quarter. Private Advisor Group LLC grew its position in Recursion Pharmaceuticals by 103.8% in the fourth quarter. Private Advisor Group LLC now owns 31,427 shares of the company’s stock worth $212,000 after acquiring an additional 16,008 shares in the last quarter. Finally, Global Retirement Partners LLC grew its position in Recursion Pharmaceuticals by 31.5% in the fourth quarter. Global Retirement Partners LLC now owns 31,297 shares of the company’s stock worth $212,000 after acquiring an additional 7,500 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Leerink Partners lowered their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. KeyCorp lowered their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Finally, Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $8.25.

Recursion Pharmaceuticals Trading Up 6.9 %

NASDAQ:RXRX opened at $6.35 on Monday. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of -4.15 and a beta of 0.85. The company’s 50 day moving average price is $7.54 and its 200-day moving average price is $7.02. Recursion Pharmaceuticals, Inc. has a 52 week low of $5.60 and a 52 week high of $12.36. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The company had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm’s revenue for the quarter was down 57.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.42) EPS. On average, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.